介孔生物活性玻璃材料在模拟体液中的用量对考察其体外生物活性的影响

制备了具有骨修复性能的新型介孔生物玻璃(mesoporous bioactive glass, MBG)材料. 在其它条件相同时改变MBG在模拟生理体液(simulated body fluid, SBF)中的用量比(0.0001～0.002 g/mL), 考察了材料的体外生物活性. 用等离子体原子发射光谱测定了不同反应时间SBF中钙、磷、硅物种的浓度; 用傅立叶红外光谱和电子扫描显微镜对材料进行了表征. 结果表明: MBG材料表面羟基磷灰石的形成速度和材料在SBF中的用量比直接相关, 其中用量比在0.001 g/mL时表现出最佳的体外生物活性. 最佳用量比的确定, 对于深入理解MBG材料的结构与体外活性的关联, 筛选具有更佳生物活性的MBG材料有着重要的意义.

Influence of the Dosage of Mesoporous Bioactive Glass in Simulated Body Fluid on the in vitro Bioactivity Evaluation

Mesoporous bioactive glass (MBG) with bone-forming bioactivity has been synthesized. By varying the MBG dosage in simulated body fluid (SBF) while the other evaluation conditions were fixed (MBG/SBF＝0.0001～0.002 g/mL), the in vitro bioactivity of MBG was studied in details by scanning electron microscopy, Fourier-transform infrared spectroscopy, and inductive coupled plasma atomic emission spectroscopy. The results show that the rate of hydroxyapatite (HA) formation on the surface of MBG was determined by the MBG dosage in SBF, and the fastest HA formation process was observed at MBG/SBF＝0.001 g/mL. Studying the influence of the dosage on the in vitro bioactivity of MBG was important to further understand the structure-bioactivity correlation of this family of biomaterials. Moreover, the choice of an ideal MBG/SBF ratio was practically advantageous for evaluating new MBG materials with better in vitro bioactivity.